Journal

Advancements and future trends of immunotherapy in light-chain amyloidosis

Read time: 1 mins

Published:1st Mar 2023

Author: Mahadevia H, Ponvilawan B, Sharma P, Al-Obaidi A, Qasim H, Koyi J et al.

Source: Critical Reviews in Oncology/Hematology

Availability: Pay for access, or by subscription

Ref.:Crit Rev Oncol Hematol. 2023 Mar;183:103917.

DOI:10.1016/j.critrevonc.2023.103917

Advancements and future trends of immunotherapy in light-chain amyloidosis

Light-chain (AL) amyloidosis is a type of plasma cell neoplasm with abnormal monoclonal immunoglobulin light-chain production and their subsequent deposition in tissues causing end-organ damage. In addition to existing treatments including autologous stem cell transplantation, there is a need for other approaches for eradicating abnormal plasma cells and amyloid tissue deposits. Treatment strategies of AL amyloidosis are mostly based on medications that are effective in multiple myeloma due to similar cell of origin. Daratumumab along with proteasome inhibitors and corticosteroids has become standard of care for AL amyloidosis. Another appealing approach is disassembling amyloid deposits with hope to potentially reverse the damage done by the disease. This was met with promising results for CAEL-101 and birtamimab. Although still in early stages, novel treatment options in pipeline, including antibody-drug conjugates, bispecific T-cell engagers, and chimeric antigen receptor T cell therapy may diversify the treatment armamentarium of AL amyloidosis in the future.

Read abstract on library site Access full article